Helmholtz Gemeinschaft


Pain, depression and quality of life in adults with MOG-antibody associated disease

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Pain, depression and quality of life in adults with MOG-antibody associated disease
Creators Name:Asseyer, S. and Henke, E. and Trebst, C. and Hümmert, M.W. and Wildemann, B. and Jarius, S. and Ringelstein, M. and Aktas, O. and Pawlitzki, M. and Korsen, M. and Klotz, L. and Siebert, N. and Ruprecht, K. and Bellmann-Strobl, J. and Wernecke, K.D. and Häußler, V. and Havla, J. and Gahlen, A. and Gold, R. and Paul, F. and Kleiter, I. and Ayzenberg, I.
Abstract:BACKGROUND AND PURPOSE: Myelin oligodendrocyte glycoprotein-antibody (MOG-ab)-associated disease (MOGAD) is an inflammatory autoimmune condition of the CNS. However, data on pain and depression have remained scarce. The aim of this study was to assess features of chronic pain and depression as well as their impact on health-related quality of life (hr-QoL) in MOGAD. METHODS: Patients with MOGAD were identified in the Neuromyelitis Optica Study Group (NEMOS) registry. Data were acquired by a questionnaire, including clinical, demographic, pain (PainDetect, Brief Pain Inventory - short form, McGill Pain Questionnaire - short form), depression (Beck Depression Inventory-II), and hr-QoL (Short Form-36 Health Survey) items. RESULTS: Twenty-two of 43 patients suffered from MOGAD-related pain (11 nociceptive, 8 definite neuropathic, 3 possible neuropathic) and 18 from depression. Patients with neuropathic pain had highest pain intensity and most profound ADL impairment. Fifteen patients reported spasticity-associated pain, including four with short-lasting painful tonic spasms. Later disease onset, profound physical impairment and depression were associated with chronic pain. Physical QoL was more affected in pain-sufferers (p<0.001) than in pain-free patients, being most severely reduced by neuropathic pain (p=0.016). Pain severity, visual impairment, and gait impairment independently predicted lower physical QoL. Depression was the only factor reducing mental QoL. Twelve patients received pain medication, still suffering from moderate pain (pain severity 4.6±2.3). Only four out of ten patients with moderate to severe depression took antidepressants. CONCLUSIONS: Being highly prevalent, pain and depression strongly affect QoL and ADL in MOGAD. Both conditions remain insufficiently controlled in real-life clinical practice.
Keywords:Depression, MOG-Antibody Associated Disease, Pain, Quality of Life, Spasticity
Source:European Journal of Neurology
Page Range:1645-1658
Date:May 2021
Official Publication:https://doi.org/10.1111/ene.14729
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library